OnCo
ideasIdea

Collect and freeze T cells at diagnosis for high-risk patients, before chemotherapy

By the time patients need CAR-T their immune cells are often exhausted by earlier treatment. Storing healthy cells early would improve manufacturing success and cut the wait.

Manufacturing failures and poor CAR-T fitness are associated with prior lines of chemotherapy, bendamustine exposure and low lymphocyte counts. Collecting and cryopreserving autologous lymphocytes at diagnosis or first relapse for patients with a high probability of later needing CAR-T (high-risk large B-cell lymphoma, high-risk myeloma) would supply fitter starting material and remove apheresis scheduling from the critical path. The proposal is a prospective banking programme with defined eligibility, consent and storage funding, and a regulatory position on the use of banked material.

Hypothesis
Patients treated from banked early-collected cells have a manufacturing failure rate below 3% (versus 5-15% from late apheresis), a shorter referral-to-infusion interval by at least ten days, and higher CAR-T expansion and durable response rates.
Rationale
T-cell fitness is the strongest product-level predictor of CAR-T outcome, and it declines with each line of therapy; banking is routine for stem cells in myeloma and the storage cost is modest relative to the therapy.
What would test it
Prospective cohort banking cells in 300 newly diagnosed high-risk lymphoma patients, comparing manufacturing metrics and outcomes for those later needing CAR-T against contemporaneous patients apheresed at relapse.
Maturity
early clinical
Who has to act
clinic
Cost to try
Medium ($1M to $50M)
Years to first evidence
4
Bottlenecks it attacks

Connected

4top

Pages like this

not linked directly; found by shared links

cancers

2
Diffuse large B-cell lymphomaMultiple myeloma

technologies

1
CAR-T cell therapy

bottlenecks

1
Manufacturing cost and time for living and radioactive medicines